MacroGenics | MGNX - Assets


MacroGenics reported $345.41M in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
AbbVie USD 135.12B 1.35B Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
AstraZeneca USD 115.83B 1.82B Jun/2026
Biogen USD 32.09B 2.6B Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Daiichi Sankyo JPY 4.11T 109.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Genmab DKK 12.52B 139M Jun/2026
Geron USD 519.01M 15.11M Jun/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
J&J USD 201.06B 167M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
MacroGenics USD 345.41M 127.54M Jun/2026
Merck USD 129.8B 1.12B Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 41.73B 861.8M Jun/2026
Roche Holding CHF 98.2B 2.5B Jun/2026
Xencor USD 724.96M 11.89M Jun/2026